Venetoclax

9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
1:00
What trial data in CLL to watch out for at ASH 2018
Stephan Stilgenbauer
2:33
Looking to the future in CLL treatment
John Seymour
0:49
UK-based CLL trials to look out for at ASH 2018
Peter Hillmen
1:09
Novel ventoclax combinations for CLL
Eva Kimby
2:21
UK-based CLL clinical trials to look forward to
Daniel Catovsky
2:48
Genomics shed light on targeted treatment for myeloma
Nikhil Munshi
1:39
Are BCL2 and MCL1 inhibitors the key against myeloma?
Enrique Ocio
3:26
Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)
Noopur Raje
1:56
Mapping the genomic landscape of Waldenström’s Macroglobulinemia
Steven Treon
1:59
From clinical trials to routine testing: the potential of MRD in CLL
Barbara Eichhorst
2:20
CAR-T therapy as a replacement for triple combination therapy in CLL
Barbara Eichhorst
2:10
Triple combination therapy in CLL
Barbara Eichhorst
2:28
Medication over chemoimmunotherapy? How best to treat CLL
Barbara Eichhorst
7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
1:28
Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Nitin Jain
The content of VJHemOnc is intended for healthcare professionals